Skip to content

US · AVIR · BIOTECHNOLOGY

Atea Pharmaceuticals, Inc. (AVIR) intrinsic value and stock valuation

$3.96as of 2026-11-21 · Mkt cap 420.14M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Atea Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values AVIR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AVIR’s statements →

Atea Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02110 ateapharma.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-158.35M
20182025
Free cash flow
-$-132.03M
20182025
Total equity
$275.4M-12.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$351.4M
Operating income-$-180.89M-$-192.95M-$-164.16M-$-130.65M$138.4M
Net income-$-158.35M-$-168.38M-$-135.96M-$-115.91M$121.2M
EPSd-$-1.94M-$-2M-$-1.63M-$-1.39M$1.37M
Operating cash flow-$-132.03M-$-135.5M-$-85.39M-$-120.98M-$-87M
Capital expenditure$0.00$0.00$0.00-$-1.94M-$0.00
Free cash flow-$-132.03M-$-135.5M-$-85.39M-$-122.92M-$-87.01M
Total assets$315.2M$464.7M$595M$666.7M$772.9M
Total debt$840K$1.64M$2.4M$3.12M$200K
Net debt-$-94.87M-$-63.05M-$-141.42M-$-643.59M-$-764.18M
Total equity$275.4M$438.9M$555.2M$640.6M$710.1M
Cash and short-term investments$301.8M$454.7M$578.1M$646.7M$764.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$351.4M
Cost of revenue$0.00$83.4M$70.1M$62.4M$167.2M
Gross profit$0.00-$-83.37M-$-70.09M-$-62.39M$184.2M
Research and development expenses$148M$145.4M$132.8M$88.8M$167.2M
Selling, general and administrative expenses$32.9M$48.9M$49.9M$48.7M$45.8M
Other expenses$0.00-$-84.67M-$-88.69M-$-69.29M-$-167.21M
Operating expenses$180.9M$109.6M$94.1M$68.3M$45.8M
Cost and expenses$180.9M$193M$164.2M$130.7M$213M
Interest income$16.4M$25.5M$29.2M$11.2M$210K
Interest expense$0.00$0.00$0.00$11.2M$0.00
Depreciation and amortization$420K$420K$420K$260K$30K
Ebitda-$-164.09M-$-131.8M-$-119.59M-$-110.84M$138.6M
Operating income-$-180.89M-$-192.95M-$-164.16M-$-130.65M$138.4M
Total other income/expenses, net$16.4M$25.5M$29.2M$11.2M$210K
Income before tax-$-164.51M-$-167.46M-$-134.94M-$-119.5M$138.6M
Income tax expense-$-6.16M$930K$1.02M-$-3.59M$17.4M
Net income-$-158.35M-$-168.38M-$-135.96M-$-115.91M$121.2M
Weighted average shares outstanding$81.5M$84.3M$83.4M$83.3M$82.8M
Weighted average diluted shares outstanding$81.5M$84.3M$83.4M$83.3M$88.3M
Balance sheet
20252024202320222021
Cash and short-term investments$301.8M$454.7M$578.1M$646.7M$764.4M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$311M$462.4M$590.5M$660.9M$772.4M
Property, plant and equipment, net$1.09M$2.12M$3.12M$4.09M$180K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$200K$300K
Total non-current assets$4.23M$2.31M$4.51M$5.79M$490K
Total assets$315.2M$464.7M$595M$666.7M$772.9M
Accounts payable$13M$4.46M$4.25M$2.55M$4.53M
Short-term debt$840K$800K$760K$720K$200K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$39.8M$18.6M$32.4M$18.5M$56.9M
Long-term debt$0.00$840K$1.64M$2.4M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$7.2M$7.4M$7.66M$5.93M
Capital lease obligations$0.00$1.64M$2.4M$3.12M$200K
Total liabilities$39.8M$25.8M$39.8M$26.1M$62.8M
Common stock$80K$80K$80K$80K$80K
Retained earnings-$-522.57M-$-364.22M-$-195.84M-$-59.88M$56M
Accumulated other comprehensive income (loss)$170K$230K$210K-$-680K-$0.00
Total equity$275.4M$438.9M$555.2M$640.6M$710.1M
Total investments$206.1M$390M$434.3M$200K$300K
Total debt$840K$1.64M$2.4M$3.12M$200K
Net debt-$-94.87M-$-63.05M-$-141.42M-$-643.59M-$-764.18M
Cash flow statement
20252024202320222021
Net income-$-158.35M-$-168.38M-$-135.96M-$-115.91M$121.2M
Depreciation and amortization$420K$420K$420K$260K$30K
Stock-based compensation$20.7M$51.8M$49.4M$46.7M$39.6M
Change in working capital$16.5M-$-7.48M$16.2M-$-46.59M-$-247.84M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$8.49M$210K$1.7M-$-1.98M$10.3M
Net cash provided by operating activities-$-132.03M-$-135.5M-$-85.39M-$-120.98M-$-87M
Investments in property, plant and equipment$0.00$0.00$0.00-$-1.94M-$0.00
Acquisitions, net$0.00$0.00$0.00$450K$0.00
Net cash used for investing activities$188.8M$56.1M$40.3M-$-455.41M-$0.00
Common stock issued$260K$270K$260K$230K$1.47M
Common stock repurchased-$-25.52M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-25.75M$270K$260K$370K$1.47M
Net change in cash$31M-$-79.13M-$-44.84M-$-576.02M-$-85.54M
Cash at end of period$95.7M$64.7M$143.8M$188.7M$764.7M
Operating cash flow-$-132.03M-$-135.5M-$-85.39M-$-120.98M-$-87M
Capital expenditure$0.00$0.00$0.00-$-1.94M-$0.00
Free cash flow-$-132.03M-$-135.5M-$-85.39M-$-122.92M-$-87.01M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Atea Pharmaceuticals, Inc.

        Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

        CEO
        Jean-Pierre Sommadossi
        Employees
        55
        Beta
        0.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Atea Pharmaceuticals, Inc. (AVIR)?

        InvestorsCraft does not currently publish an intrinsic value for AVIR. How the IC value is calculated.

        Is AVIR undervalued?

        InvestorsCraft does not publish an undervaluation signal for AVIR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.